Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03043378
Other study ID # 2016-0901
Secondary ID NCI-2018-01268
Status Completed
Phase
First received
Last updated
Start date July 31, 2018
Est. completion date March 23, 2023

Study information

Verified date March 2023
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this research study is to learn how frequently cancer patients in the Supportive Care Center have chronic, non-malignant pain. Chronic, non-malignant pain is pain that is neither related to cancer nor its treatment and lasts beyond the normal tissue healing time of 3 months.


Description:

If participant is found to be eligible and agrees to take part in this study, participant will be asked to complete 3 questionnaires about participant's pain, pain level, and what drugs participant takes to treat participant's pain. Participant will also be asked a few questions about tobacco use. These questionnaires should take about 20 minutes to complete. Researchers will also collect information from participant's medical record such as participant's date of birth, sex, race, marital status, economic background, and medical history. Length of Study: Participation on this study will be over after participant has completed the last questionnaire. This is an investigational study. Up to 200 participants will be enrolled in this study. All will take part at MD Anderson.


Recruitment information / eligibility

Status Completed
Enrollment 201
Est. completion date March 23, 2023
Est. primary completion date March 23, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Diagnosis of cancer with or without active disease 2. Consultation visit at an outpatient supportive care clinic 3. Age 18 or greater 4. Report of having pain within the last 3 months Exclusion Criteria: 1) Memorial Delirium Assessment Scale >13

Study Design


Related Conditions & MeSH terms

  • Malignant Neoplasms of Independent (Primary) Multiple Sites
  • Neoplasms

Intervention

Behavioral:
Questionnaires
Participants complete three questionnaires at consultation visit.

Locations

Country Name City State
United States University of Texas MD Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency of Chronic Non-Malignant Pain Among Cancer Patients Frequency assessed by Edmonton Symptom Assessment Scale (ESAS-FS) 1 day
Primary Frequency of Chronic Non-Malignant Pain Among Cancer Patients Frequency assessed by Brief Pain Inventory. 1 day
Primary Frequency of Chronic Non-Malignant Pain Among Cancer Patients Frequency assessed by the Charlson Comorbidity Index. 1 day
Primary Frequency of Chronic Non-Malignant Pain Among Cancer Patients Frequency assessed by Pain Characteristic Survey. 1 days
Primary Frequency of Chronic Non-Malignant Pain Among Cancer Patients Frequency assessed by Karnofsky Performance Scale. 1 day
See also
  Status Clinical Trial Phase
Completed NCT03168763 - Effect of Physician Attire on Patients' Preference of Physician N/A
Completed NCT02957565 - Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During an Outpatient Palliative Care Visit N/A
Recruiting NCT03093909 - Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases Phase 1
Active, not recruiting NCT02911064 - Expectations Regarding Mobility and Self-Care
Withdrawn NCT03177681 - The Effect of Yogurt in Cancer Patient With Moderate Gastrointestinal (GI) Symptoms N/A
Active, not recruiting NCT03435952 - Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT Phase 1
Completed NCT03042884 - Wearable Exercise Trackers in Cancer Rehabilitation N/A
Completed NCT03035448 - Communication Strategies to Introduce Psychology Services N/A
Withdrawn NCT02915172 - Lenvatinib and Capecitabine in Patients With Advanced Malignancies Phase 1
Withdrawn NCT03115528 - Difference in the Estimation of Prognosis